Cure of a CD20-Positive Peripheral T-cell Lymphoma-NOS with CHOPE Regimen plus Surgery A Case Report and Literature Review

Chenyu ChiShuo WangMan XuYue ShiXuehong Ran^*

• Weifang People's Hospital, Shandong Second Medical University, Weifang, China

Peripheral T-cell lymphoma non-specific type ( PTCL-NOS ) is the most common subtype of mature T-cell tumors, which is clinically characterized by high invasiveness and poor prognosis. It is worth noting that PTCL-NOS rarely abnormally expresses B-cell antigens ( such as CD20 ). This rare immunophenotype makes it easily confused with B-cell non-Hodgkin 's lymphoma ( B-NHL ), which brings challenges to clinical diagnosis and may lead to wrong treatment decisions. At present, CHOP regimen, as the first-line standard therapy for PTCL-NOS, has the limitations of low complete remission rate and high recurrence risk. In order to improve the efficacy, recent studies have confirmed that the combination of etoposide ( CHOPE regimen ) on the basis of CHOP regimen can significantly improve the treatment response for newly diagnosed patients aged ≤ 65 years. This paper reports a rare case of PTCL-NOS with abnormal expression of CD20 in the tongue. The patient received 4 cycles of CHOPE regimen after surgical resection of the primary tumor and underwent PET / CT mid-term evaluation. Through this case, we aim to further explore the pathological diagnosis difficulties of such rare cases and preliminarily evaluate the clinical application value of CHOPE regimen.